Sutro Biopharma's CEO will present at the J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco.
Quiver AI Summary
Sutro Biopharma, Inc., a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced that CEO Jane Chung will speak at the upcoming J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 AM PT in San Francisco. Attendees can watch a live webcast of her presentation through the company’s website, with an archived version available for 30 days afterward. Sutro is focused on developing next-generation ADCs that improve drug exposure and minimize side effects for cancer patients, particularly through innovative dual-payload systems. The company aims to address significant gaps in treatment options for various cancers.
Potential Positives
- Presentation by the CEO at a prestigious healthcare conference enhances visibility and credibility of Sutro Biopharma in the biotech sector.
- Focus on next-generation antibody-drug conjugate (ADC) technology positions the company as an innovator aiming to address critical needs in cancer treatment.
- Potential to attract investment and partnership opportunities through the showcasing of its pipeline targeting large oncology markets.
- Access to a live webcast may engage a broader audience and demonstrate transparency and commitment to investor relations.
Potential Negatives
- None
FAQ
When is Sutro Biopharma's presentation at the J.P. Morgan Healthcare Conference?
Sutro Biopharma's presentation is scheduled for Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET.
Where can I watch the live webcast of the presentation?
The live webcast will be accessible through the Events & Presentations page of the Investor Relations section on Sutro's website.
What are antibody drug conjugates (ADCs)?
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine antibodies with cytotoxic drugs to improve treatment efficacy and reduce side effects.
How does Sutro Biopharma's ADC platform differ from others?
Sutro's ADC platform optimizes antibodies, linkers, and payloads, allowing for single- and dual-payload ADCs designed to improve drug exposure and reduce resistance.
Where can I find more information about Sutro Biopharma?
More information can be found on Sutro Biopharma's website at www.sutrobio.com or by following them on social media @Sutrobio.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STRO Insider Trading Activity
$STRO insiders have traded $STRO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STRO stock by insiders over the last 6 months:
- CONNIE MATSUI purchased 50,000 shares for an estimated $39,950
- GREGORY K. CHOW (CFO) purchased 19,750 shares for an estimated $15,997
- HANS-PETER GERBER (CHIEF SCIENTIFIC OFFICER) purchased 17,000 shares for an estimated $13,606
- JANE CHUNG (Chief Executive Officer) purchased 12,500 shares for an estimated $10,011
- DAVID PAULING (Chief Admin. Ofcr. & GC) purchased 12,504 shares for an estimated $9,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STRO Hedge Fund Activity
We have seen 31 institutional investors add shares of $STRO stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC removed 688,850 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $598,197
- AQR CAPITAL MANAGEMENT LLC removed 658,267 shares (-65.0%) from their portfolio in Q3 2025, for an estimated $571,639
- PRUDENTIAL FINANCIAL INC removed 569,080 shares (-94.1%) from their portfolio in Q3 2025, for an estimated $494,189
- RENAISSANCE TECHNOLOGIES LLC added 511,600 shares (+56.0%) to their portfolio in Q3 2025, for an estimated $444,273
- CANTOR FITZGERALD, L. P. removed 500,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $434,200
- JACOBS LEVY EQUITY MANAGEMENT, INC added 445,750 shares (+inf%) to their portfolio in Q3 2025, for an estimated $387,089
- VANGUARD GROUP INC removed 432,264 shares (-10.5%) from their portfolio in Q3 2025, for an estimated $375,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STRO Price Targets
Multiple analysts have issued price targets for $STRO recently. We have seen 2 analysts offer price targets for $STRO in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $10.0 on 12/22/2025
- Derek Archila from Wells Fargo set a target price of $3.0 on 08/12/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA.
A live webcast of the presentation will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com . An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit
www.sutrobio.com
.
Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
[email protected]
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]
